Table 1.

Study characteristics

Study	Design	Subjects	Inclusion criteria	Exclusion criteria	Primary endpoint	Mean length follow-up
Cavender	Cohort study	28,936	STEMI with CAD of > 1 major artery	LM, staged PCI (multiple PCIs before hospital discharge), thrombolytic	In-hospital mortality	In-hospital
Corpus	Cohort study	532	STEMI with > 70 % stenosis of ≥ 2 arteries	PCI of graft or after angioplasty, LM, planned staged revascularisation	MACE	12 months
Di Mario	Randomised	69	STEMI with MVD and 1–3 lesions in non-culprit artery technically amenable to revascularisation by stent	Lesion in vein and arterial grafts, prior angioplasty, thrombolytic, cardiogenic shock, LM	Repeat revascularisation	12 months
Dziewierz	Cohort study	777	STEMI with MVD 2–3 lesions in non-culprit artery	CABG	All-cause mortality	12 months
Hannan	Cohort study	1006	STEMI with MVD	LM disease, prior thrombolysis, prior CABG, cardiogenic shock, missing EF	All-cause mortality	42 months
Khattab	Cohort study	73	STEMI with > 70 % stenosis of ≥ 2 coronary arteries or major branches	Non-IRA diameter < 2.5 mm, LM disease, previous MI	MACE	12 months
Kornowski	Cohort study	668	STEMI with MVD	TIMI flow < 3 in non-IRA	MACE	12 months
Ochala	Randomised	92	STEMI with > 70 % stenosis of ≥ 2 coronary arteries, successful PCI of IRA	Cardiogenic shock, LM disease, pervious CABG, renal insufficiency, severe valvular disease	Improvement in LVEF	6 months
Politi	Randomised	214	STEMI with > 70 % stenosis of ≥ 2 coronary arteries or major branches	Cardiogenic shock, LM > 50 %, pervious CABG, severe valvular heart disease or unsuccessful procedure	MACE	30 months
Qarawani	Cohort study	120	STEMI with > 70 % multivessel narrowing	Cardiogenic shock, LM disease	Clinical outcome	12 months
Roe	Cohort study	129	STEMI with ≥ 50 % stenosis of ≥ 1 non-culprit artery in addition to culprit IRA	PCI of branch vessels of IRA, LM disease	MACE (death, re-MI, and revascularisation)	6 months
Toma	Cohort study	2201	STEMI with > 70 % stenosis of > 1 major epicardial artery and/or a non-IRA requiring intervention	PCI on LM, second intervention in the culprit artery	MACE (death, CHF, shock)	3 months
Varani	Cohort study	399	STEMI with > 70 % stenosis of ≥ 2 epicardial arteries or major branches	Occlusion after prior angioplasty, cardiogenic shock, pulmonary oedema	Death and repeat revascularisation	1 month
Wald	Randomised	465	STEMI with ≥ 50 % stenosis of ≥ 1 non-IRA in addition to IRA	Cardiogenic shock, LM > 50 %, pervious CABG	MACE	23 months
Gershlick	Randomised	294	STEMI with > 70 % stenosis of ≥ 2 epicardial arteries or major branches (> 2 mm)	Cardiogenic shock, previous MI, pervious CABG, chronic kidney disease, CTO	MACE	12 months

CABG coronary artery bypass graft, CAD coronary artery disease, CHF congestive heart failure, CTO chronic total occlusion, IRA infarct-related artery, LM left main artery, LVEF left ventricular ejection fraction, MACE major adverse cardiac events, MI myocardial infarction, MVD multivessel disease, PCI percutaneous coronary intervention, STEMI ST-elevation myocardial infarction, TIMI thrombolysis in myocardial infarction